

Target	Subcellular localisation	Molecular function	Drug name DrugBank ID	Mechanism Study status	Drug name DrugBank ID	Mechanism Study status
MMP7	extracellular	Degrades casein, gelatins of types I, III, IV, and V, and fibronectin. Activates procollagenase	marimastat DB00786	MMP-inhibitor Phase 3 ClinicalTrials	N.A	N.A
CXCR2	plasmamembrane	Receptor for interleukin-8 which is a powerful neutrophil chemotactic factor	reparixin DB12614	chemokine receptor antagonist Phase 3 ClinicalTrials	danirixin DB11922	chemokine receptor antagonist Phase 2 ClinicalTrials
CES1	cytoplasm	Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs	apoptosis- activator-II	CES- inhibitor preclinical	avasimibe DB06442	ACAT inhibitor Phase3 PubMed
ITGB6	plasmamembrane	Integrin alpha-V:beta-6) is a receptor for fibronectin and cytactin	integrin-antagonist-1	integrin antagonist Phase 1 ClinicalTrials	N.A	N.A
BIRC3	nucleus	Multi-functional protein which regulates caspases, apoptosis, inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation.	birinapant DB11782	XIAP inhibitor Phase 2 ClinicalTrials	AT-406	IAP antagonist Phase 1 ClinicalTrials
BCAT1	cytoplasm, mitochondrion	Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine.	L- glutamate DB00142	glutamate receptor agonist Launched	N.A	N.A
ALDH2	Mito-chondrion	This protein is involved the subpathway that synthesizes acetate from ethanol	disulfiram DB00822	ALDH-inhibitor launched	daidzin DB02115	glycosyloxyisoflavone Phase 1 ClinicalTrials
TNFSF10	plasmamebrane, extracellular	Cytokine that induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3	ONC201 DB14844	AKT-inhibitor Phase 2 ClinicalTrials	N.A	N.A
MYC	nucleus	Transcription factor that binds DNA in a non-specific manner. Activates the transcription of growth-related genes, promoting VEGFA production and subsequent angiogenesis	AZD5153	bromodomain inhibitor Phase1 ClinicalTrials	mivebresib	bromodomain inhibitor Phase 1 ClinicalTrials

CDH2	plasmamembrane	Calcium-dependent cell adhesion protein. Acts as a regulator of neural stem cells quiescence by mediating anchorage of neural stem cells	exherin	cadherin antagonist Phase 2 ClinicalTrials	N.A	N.A
EGLN2	nucleus	Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins	FG-2216 DB08687	hypoxia inducible factor prolyl hydroxylase inhibitor Phase 2 ClinicalTrials	vadadustat DB12255	hypoxia inducible factor prolyl hydroxylase inhibitor Phase 3 ClinicalTrials
PAK7	nucleus, mitochondrion	Serine/threonine protein kinase that plays a role in a variety of different signaling pathways including cytoskeleton regulation, cell migration, proliferation or cell survival	GSK690693 DB12745	AKT inhibitor Phase 1 ClinicalTrials	N.A	N.A
TPO	plasma-mebrane, extracellular	Iodination and coupling of the hormonogenic tyrosines in thyroglobulin to yield the thyroid hormones T ₃ and T ₄	carbimazole DB00389	antithyroid agent Launched	propylthiouracil DB00550	thyroid peroxidase inhibitor Launched